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Intentional Flecainide Overdose
Nicholas Coriasso, D.O., Daniel Grahf, M.D., Mir Basir, D.O.,
Department of Internal Medicine, Department of Cardiology,
Henry Ford Hospital, Detroit, MI

INTRODUCTION

CASE OUTCOME

• 32 year old male with a past medical history of atrial fibrillation and
depression presented to the hospital after an intentional overdose with
flecainide and metoprolol succinate
• Home medications = flecainide & metoprolol succinate
• Patient was lucid in the Emergency Department (ED) and stated that he took
thirty to forty 100 mg flecainide tablets along with an unknown amount of
metoprolol succinate

• In the CICU, toxicology escalated interventions to include 20% intra-lipid
emulsion followed by high dose insulin given escalating vasopressor
requirements
• Thirty six hours into the admission, patient had progressed to multi-organ
failure
• Exam revealed fixed and dilated pupils, corneal reflexes were absent
bilaterally, and gag reflex was absent
• After discussion with family, the decision was made to withdraw care, and the
patient passed away

ELECTROCARDIOGRAPHIC CHARACTERISTICS

Figure 1: https://www.huffpost.com/entry/drug-overdose-deaths_n_7603302

INITIAL WORK UP & EARLY MANAGEMENT
• Vitals in the ED = mild hypotension but otherwise hemodynamically stable
• Lab values = serum K+ 3.4 mmol/L, Mg2+ 1.9 mg/dL, and lactate 4.4
mmol/L
• Toxicology was consulted & recommended starting a sodium bicarbonate
infusion along with intermittent 3% normal saline boluses (with a goal pH >
7.5) to prevent QRS widening
• Patient was then admitted to the medical intensive care unit (MICU)

CONTINUED CASE

• Initial electrocardiographic (EKG) characteristics (two hours after ingestion
of flecainide) = wide complex tachycardia (QRS 142 ms) with a PR of 210
ms and QTc of 517
• This will be referred to as hour two (HR2)
• Patient did have an old EKG from 2018 = normal sinus rhythm with normal
PR & QRS intervals (reference PR < 200 ms & QRS < 120 ms)
• HR3.5 = Continued widening of QRS (162 ms) , PR (224 ms), & QTc (579)
• HR5.5 = Patient developed a Brugada pattern in V1-2, which has been well
documented in the literature in regards to flecainide toxicity [1,2,3]
• HR6.0 = Brugada pattern becomes more pronounced & QRS (172 ms)
continues to widen; PR (188 ms) & QTc (552) stabilize
• HR7.5 = Immediately prior to cardiac arrest; QRS widens to 180 ms, PR
widens to 240 ms, & QTc prolongs to 585
• Shortly thereafter, patient goes into VF arrest & subsequently PEA
• HR13.5 = Status post VA-ECMO placement
• Patient was given 20% intra-lipid emulsion & high dose insulin was initiated
given increasing vasopressor requirements
• HR17.5 = Ventricular pacing and QRS widening (218 ms) approaching a
sinusoidal pattern; this was the last EKG obtained prior to withdrawal of care

• In the MICU, patient had a subsequent cardiac arrest
• The initial rhythm revealed ventricular fibrillation (VF) but this quickly
degenerated to pulseless electrical activity (PEA) prior to any attempted
defibrillation
• Given on-going cardiopulmonary resuscitation (CPR), patient underwent
placement of VA-ECMO along with a transvenous pacemaker
• Patient was then transferred to the cardiac intensive care unit (CICU)

FLECAINIDE
• Flecainide acetate is a class 1C antiarrhythmic most often used for
supraventricular arryhthmias
• Intentional overdose is rare and life threatening
• Flecainide depresses all conduction pathways, manifesting with prolongation
of the PR & QRS intervals on EKG, making these patients highly prone to
fatal arrhythmias [4]
• As stated flecainide toxicity has been associated with Brugada pattern
• It has been postulated in a number of case reports that the Brugada pattern
seen in flecainide toxicity may actually be underlying Brugada Syndrome
unveiled by the sodium channel blockade of flecainide [2]

MECHANICAL CIRCULATORY SUPPOPT
• One large study (systemic review of 21 articles) evaluated EKG
characteristics in flecainide overdose along with the subsequent need for
mechanical circulatory support (MCS) & mortality
• Study compared patients with QRS </= 200 ms & those with QRS > 200 ms
• Patients with a QRS > 200 ms required MCS more often and had higher
mortality rates [4]
• Our case demonstrated a poor outcome associated with a wide complex
tachycardia (QRS > 200) in a patient who required MCS & eventually passed
away
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